BBIO Stock: Insider Activity, Filings & Research

BridgeBio Pharma, Inc. (BBIO) — Drillr’s hub for BBIO insider activity, SEC filings, earnings signals and AI research. Over the trailing 3 months, BBIO insiders filed 0 open-market buys and 39 sales (SEC Form 4).

Over the trailing 90 days, insiders recorded 0 open-market purchases and 39 sales, a net selling of $18.7M. The largest was Kumar Neil (director, officer: Chief Executive Officer) selling $1.5M. The stock fell 1.6% over three months. Institutional holders were net accumulators over recent 13F filings. Insider sentiment scores 0/100.

Updated Jun 4, 2026 · based on SEC Form 4 filings · not investment advice

Sentiment

0/100

Buys (3m)

Sells (3m)

Net (3m)

-$18.7M

Insider trades by month Buys Sells

Dec

Jan

Feb

Mar

Apr

May

Context3-month price -1.6%Institutions accumulating (13F)

Date	Insider	Type	Shares	Price
May 26, 2026	Kumar Neildirector, officer: Chief Executive Officer	Sell	11,250	$70.48
May 26, 2026	Kumar Neildirector, officer: Chief Executive Officer	Sell	5,072	$69.22
May 26, 2026	Kumar Neildirector, officer: Chief Executive Officer	Sell	800	$70.92
May 26, 2026	Kumar Neildirector, officer: Chief Executive Officer	Sell	6,725	$68.30
May 26, 2026	Kumar Neildirector, officer: Chief Executive Officer	Sell	2,256	$67.57
May 19, 2026	Scott Randal W.director	Sell	6,200	$66.69
May 19, 2026	Scott Randal W.director	Sell	2,088	$67.53
May 19, 2026	Kumar Neildirector, officer: Chief Executive Officer	Option	6,519	—
May 19, 2026	Kumar Neildirector, officer: Chief Executive Officer	Option	19,599	—
May 19, 2026	Kumar Neildirector, officer: Chief Executive Officer	Option	11,553	—
May 19, 2026	Trimarchi Thomasofficer: President and CFO	Tax	22,781	$66.13
May 19, 2026	Kumar Neildirector, officer: Chief Executive Officer	Tax	36,236	$66.13
May 19, 2026	Apuli Maricelofficer: Chief Accounting Officer	Tax	4,714	$66.13
May 19, 2026	Scott Randal W.director	Option	10,000	$16.75
May 19, 2026	Scott Randal W.director	Sell	1,512	$68.23

Source: BBIO SEC Form 4 filings, latest May 26, 2026. For informational purposes only — not investment advice.

Overview

BridgeBio Pharma, Inc. (NASDAQ:BBIO) is a biotechnology company founded in 2015 and headquartered in Palo Alto, California. The company went public in June 2019 and focuses on discovering, developing, and delivering medicines for genetic diseases. BridgeBio operates with a unique decentralized model, creating subsidiary companies around specific therapeutic programs while maintaining a centralized platform for shared resources and expertise. The company has achieved its first major commercial success with the FDA approval and launch of Attruby (acoramidis) in 2024 for the treatment of transthyretin amyloidosis cardiomyopathy (ATTR-CM), marking a significant milestone in its evolution from a pure development-stage company to a commercial enterprise.

Business

BridgeBio operates in the biotechnology sector, specifically focusing on rare genetic diseases and Mendelian disorders - conditions caused by mutations in single genes that often affect small patient populations but have devastating health impacts. The company's approach centers on developing targeted therapies for diseases with well-understood genetic causes but limited or no treatment options. The company's flagship commercial product is Attruby (acoramidis), a small molecule drug that stabilizes transthyretin (TTR) protein to treat ATTR-CM, a progressive and fatal heart disease where misfolded proteins accumulate in heart tissue. ATTR-CM affects approximately 300,000-500,000 patients globally and was historically underdiagnosed until recent advances in diagnostic techniques. BridgeBio maintains a pipeline of approximately 30 development programs spanning three main therapeutic areas. The genetic medicines division represents the largest segment, focusing on rare genetic disorders and including programs like BBP-831 for achondroplasia (a form of dwarfism), encaleret for calcium metabolism disorders, and BBP-631 for congenital adrenal hyperplasia. The oncology division develops targeted cancer therapies, while the gene therapy division works on delivering functional genes to replace defective ones. The company's business model involves creating focused subsidiary companies around specific therapeutic programs, allowing for specialized expertise and potential future spin-offs or partnerships while leveraging shared infrastructure for drug development, regulatory affairs, and manufacturing capabilities.

Revenue model

BridgeBio generates revenue through multiple streams reflecting its transition from development-stage to commercial operations. Product sales now represent the primary growth driver, with Attruby generating $36.7 million in net product revenue in Q1 2025, its first full quarter of commercial availability. The company employs a direct-pay model where patients, insurance companies, and government programs pay for the medication, with BridgeBio offering patient assistance programs including free trials and lifetime free drug access for clinical trial participants. Licensing and collaboration revenue provides another significant income source, with $79.9 million recognized in Q1 2025 primarily from milestone payments related to Attruby's European approval through partner Alexion. The company has established licensing agreements with academic institutions like Stanford University and the University of California system, as well as collaboration deals that can generate upfront payments, milestone payments, and royalties. Grant funding and research collaborations provide additional non-dilutive financing for specific programs, particularly those addressing ultra-rare diseases where government agencies and foundations support development efforts. Several factors influence BridgeBio's profitability margins. Positive factors include the premium pricing power inherent in rare disease treatments due to limited competition and high unmet medical need, the potential for multiple indications from single drug platforms (as demonstrated by encaleret's expansion from ADH1 to chronic hypoparathyroidism), and the company's decentralized model that allows for focused resource allocation. Negative factors include the high cost of clinical trials for rare diseases, the need for specialized sales forces and medical education, manufacturing complexities for small-batch production, and regulatory risks inherent in drug development where single trial failures can eliminate entire programs.

Risks & safety

BridgeBio presents a moderate margin of safety with improving fundamentals but ongoing execution risks typical of biotechnology companies. • Liquidity position: Strong with $540.6 million in cash and cash equivalents as of Q1 2025, providing approximately 2-3 years of runway at current burn rates • Cash burn: Operating cash flow negative at -$199.2 million in Q1 2025, but improving from -$195.3 million in Q4 2024 as commercial revenues begin offsetting R&D expenses • Debt levels: Minimal traditional debt with debt-to-equity ratio of -0.006, though the company carries significant contingent liabilities related to milestone payments and royalty obligations • Current ratio: Healthy at 4.57, indicating strong short-term liquidity to meet obligations • Valuation metrics: Trading at negative traditional metrics due to development-stage losses, but EV/Revenue of approximately 13x based on current run-rate commercial sales suggests reasonable valuation for a newly commercial biotech • Revenue trajectory: Strong early commercial performance with Attruby showing $36.7 million in quarterly sales in its launch phase • Pipeline risk: Concentration risk with three major Phase 3 readouts expected within the next year that could significantly impact valuation • Competitive dynamics: Operating in rare disease markets with limited competition but facing potential entry from larger pharmaceutical companies

Recent development

BridgeBio has undergone a significant transformation over the past two years, evolving from a pure development-stage company to a commercial enterprise. The most significant milestone was the FDA approval and commercial launch of Attruby in early 2024, which marked the company's first transition to generating meaningful product revenue. The launch has exceeded expectations with 2,072 unique patients receiving prescriptions through April 2025 and 756 healthcare providers writing prescriptions. The company has strategically expanded its clinical pipeline with three major Phase 3 programs expected to read out within the next year: encaleret for ADH1 (autosomal dominant hypocalcemia), a program for limb-girdle muscular dystrophy 2I, and BBP-831 for achondroplasia. Notably, encaleret has shown promising expansion potential beyond its original indication, with positive proof-of-concept data in chronic hypoparathyroidism representing a market 7-8 times larger than the original ADH1 indication. International expansion has accelerated through the partnership with Alexion, which secured European approval for Attruby and generated $79.9 million in milestone revenue in Q1 2025. This partnership model allows BridgeBio to access global markets without building international commercial infrastructure. The company has also enhanced its organizational capabilities by building commercial operations, including sales teams and patient access programs, while maintaining its decentralized R&D model. Recent strategic moves include advancing gene therapy programs and expanding into new therapeutic areas while maintaining focus on rare genetic diseases where the company has developed core competencies.

BBIO company profile · for informational purposes only — not investment advice.

Track BBIO with Drillr

SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.

Try Drillr for free